Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Laboratorios Farmaceutocos Rovi SA (ROVI) EUR0.06

Sell:€55.30 Buy:€55.60 Change: €1.30 (2.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €1.30 (2.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €1.30 (2.30%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Contact details

C/ Julian Camarillo, 35
+34 (913) 756230

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€3.17 billion
Shares in issue:
55.40 million
Madrid Stock Exchange
Madrid General Index

Key personnel

  • Juan Lopez-Belmonte Lopez
    Chairman of the Board
  • Juan Lopez-Belmonte Encina
    Chief Executive Officer, Executive Director
  • Javier Lopez-Belmonte Encina
    First Deputy Chairman of the Board, Chief Financial Officer, Executive Director
  • Ivan Jorge Lopez-Belmonte Encina
    Second Deputy Chairman of the Board, Executive Director of Corporate Development Manager
  • Beatriz Alcalde
    Sales Manager Line B
  • M. Rosario Perez
    Marketing Manager
  • Francisco Javier Angulo Garcia
    Human Resources Manager
  • Pedro Carretero Trillo
    Hospital Network Manager
  • Miguel Angel Castillo San Roman
    International & Business Development Manager
  • Mercedes Benitez Del Castillo Sanchez
    Manager - Legal Department

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.